NCT04014777View on ClinicalTrials.gov

Study of NGM621 in Participants With Geographic Atrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Geographic Atrophy
Interventions
BIOLOGICAL

NGM621

NGM621 Dose 1

BIOLOGICAL

NGM621

NGM621 Dose 2

BIOLOGICAL

NGM621

NGM621 Dose 3

BIOLOGICAL

NGM621

NGM621 Dose 4

Trial Locations (6)

32901

NGM Clinical Study Site, Melbourne

33711

NGM Clinical Study Site, St. Petersburg

77384

NGM Clinical Study Site, The Woodlands

78705

NGM Clinical Study Site, Austin

91007

NGM Clinical Study Site, Arcadia

92663

NGM Clinical Study Site, Newport Beach

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY

NCT04014777 - Study of NGM621 in Participants With Geographic Atrophy | Biotech Hunter | Biotech Hunter